EVARREST™ Fibrin Sealant Patch Post-Market Study

PHASE4CompletedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

July 1, 2013

Primary Completion Date

August 1, 2015

Study Completion Date

September 1, 2015

Conditions
HemorrhageSoft Tissue Bleeding
Interventions
BIOLOGICAL

EVARREST™ Fibrin Sealant Patch

EVARREST™ Fibrin Sealant Patch is a sterile, bio-absorbable combination product, comprised of two biological components (human plasma-derived fibrinogen and thrombin) embedded in a flexible composite patch component.

OTHER

Standard of Care

Standard of Care will be manual compression (MC) with or without a topical absorbable hemostat (TAH) or any other adjunctive hemostasis technique that is deemed by the surgeon to be his/her standard of care.

Trial Locations (1)

63110

Clinical Site #10, St Louis

All Listed Sponsors
lead

Ethicon, Inc.

INDUSTRY

NCT01902459 - EVARREST™ Fibrin Sealant Patch Post-Market Study | Biotech Hunter | Biotech Hunter